{"nctId":"NCT04976777","briefTitle":"A Study to Evaluate an Updated Dexamethasone Intravitreal (Into the Eye) Applicator in Adult Participants With Macular Edema Due to Diseases of the Retina","startDateStruct":{"date":"2021-10-12","type":"ACTUAL"},"conditions":["Macular Edema"],"count":54,"armGroups":[{"label":"Updated Dexamethasone Posterior Segment Drug Delivery System (DEX PS DDS) 0.7 mg","type":"EXPERIMENTAL","interventionNames":["Device: Updated DEX PS DDS Applicator","Drug: Dexamethasone"]},{"label":"Approved DEX PS DDS 0.7 mg","type":"ACTIVE_COMPARATOR","interventionNames":["Device: Approved DEX PS DDS Applicator","Drug: Dexamethasone"]}],"interventions":[{"name":"Updated DEX PS DDS Applicator","otherNames":[]},{"name":"Approved DEX PS DDS Applicator","otherNames":["OZURDEXÂ®"]},{"name":"Dexamethasone","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n\\- Participants with macular edema due to retinal vein occlusion (branch retinal vein occlusion or central retinal vein occlusion) or diabetic macular edema.\n\nExclusion Criteria:\n\n\\- Participants with ocular conditions in the study eye for which Dexamethasone Posterior Segment Drug Delivery System Implant is contraindicated.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants Experiencing at Least One Adverse Events (AEs)","description":"An adverse event (AE) is defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. The investigator assesses the relationship of each event to the use of study.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Dexamethasone Posterior Segment Drug Delivery System (DEX PS DDS) Updated Applicator Performance","description":"The investigator evaluated whether the updated DEX PS DDS Applicator dispensed the DEX PS DDS implant in the vitreous cavity and performed as intended, using a treatment administration assessment form.","paramType":null,"dispersionType":null,"classes":[]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":36},"commonTop":["CONJUNCTIVAL HAEMORRHAGE","INTRAOCULAR PRESSURE INCREASED","COVID-19"]}}}